Abstract:Abstract Background High density lipoprotein (HDL) exerts various atheroprotective functions including cholesterol efflux capacity (CEC). HDL can attenuate lipid burden at atherosclerotic lesion by CEC. Based on the HDL`s role for moderate atherosclerosis, HDL-cholesterol level which indicates the amount of HDL has been evaluated to assess the risk of cardiovascular disease (CVD). Nevertheless, many clinical studies demonstrated that HDL-cholesterol level does not always reflect the risk of CVD, and CEC which represents the quality of HDL is considered as surrogate biomarker for CVD. CEC is prospective biomarker for CVD risk assessment, however, CEC measurement encounters barriers for clinical application because of its requirements of cultured cell and radioactive substance for conventional CEC assay. To overcome these problems, we invented a novel CEC assay called immobilized liposome-bound gel beads (ILG) method. This method is cell-free assay and utilizes a fluorescence substance as cholesterol tracer. Although the ILG method is useful assay for clinical application, previous study revealed that bilirubin caused false positive error on CEC value. Hence, current ILG method might produce incorrect CEC evaluation for patients with hyperbilirubinemia and even healthy subjects within the range of biological variation of bilirubin. In this study, we improved the influence of bilirubin for ILG method by using bilirubin oxidase (BOD). Methods BOD (Asahi Kasei Corp.) was added to 10 mM Tris-HCl (pH 7.4) containing 150 mM of NaCl and 1 mM of Na2EDTA (Buffer A). Bilirubin from ‘Interference check A Plus’ (Sysmex Inc.) was added to serum (free-: 10 mg/dL, conjugated-:9.7 mg/dL), and apoB-depleted serum (BDS) was derived from the bilirubin additive serum using polyethylene glycol. After the prepared bilirubin additive BDS was incubated with BOD-containing Buffer A for 16 h, the absorbance spectrum was analyzed. In addition, the time course of bilirubin decrement was monitored during 16 h-incubation. We further measured the fluorescence intensity of bilirubin additive BDS incubated with BOD-containing Buffer A. Using the newly developed BOD-containing Buffer A for ILG method, CEC of bilirubin additive serum was evaluated. Finally, we measured CEC of 4 healthy individuals by conventional and the improved ILG method. The CEC value was standardized by fluorescence intensity of reference sample which was measured in every assay. Results BOD contained in Buffer A could convert bilirubin to biliverdin from results of absorbance spectrum. According to the time course of bilirubin decrement, both free- and conjugated-bilirubin were oxidized to biliverdin in approximately 6 h. By converting bilirubin to biliverdin, fluorescence light was weakened greatly. We confirmed that there was no significant difference of CEC values between non bilirubin-additive serum and bilirubin additive serum. Compared healthy individual CEC values measured by conventional and improved ILG method, all subjects showed significant decrease of CEC values from the improved method, and false positive error caused by bilirubin was ameliorated. Conclusion In this study, we achieved to improve the positive error caused by bilirubin on CEC assay using ILG method. This improvement would contribute to more accurate CEC assessment by ILG method and advance the clinical application of this method.

A novel optical assay system for bilirubin concentration measurement in whole blood

Combination of Distance-Based Paper Analytical Devices with Ionic Liquid-Based Dispersive Liquid-Liquid Microextraction for Enzyme-Free Bilirubin Quantification

A Method for Compensating Hemoglobin Interference in Total Serum Bilirubin Measurement Using a Simple Two-Wavelength Reflectance Photometer

Biomimetic Point-of-care Testing of Trace Free Bilirubin in Serum by Using Glucose Selective Capture and Surface-Enhanced Raman Spectroscopy

A-209 Application of Bilirubin Oxidase for Improvement of False Positive Error Caused by Bilirubin on Cholesterol Efflux Capacity Assay by Immobilize Liposome-Bound Gel Beads method

Noninvasive Measurement of Serum Bilirubin Employing Near-Infrared Spectroscopy

Used High Collimation UV-LEDs With a Miniaturized Optomechanical Device for the Detection of Direct Bilirubin

Spectral analysis with highly collimated mini-LEDs as light sources for quantitative detection of direct bilirubin

Ultra-low level detection of biomarker bilirubin by graphene quantum dots and bovine serum albumin enabled turn-on sensing

Determination of Bilirubin Using Near Infrared Diffuse Reflectance Spectroscopy with Selective Concentration on Β-Cyclodextrin

Polymer composite fiber-optic Fabry–Perot cavity sensor based on Ti3C2TX MXene enhanced photothermal effect for low-concentration bilirubin detection

Dual-mode Spectrum of Transmission and Fluorescence Using Single Ultraviolet LED Light Source and Their Application in Analyzing Total Bilirubin in Serum.

Conjugated Polymer Nanoparticles as a Fluorescence Probe for Amplified Detection of Human Serum Bilirubin

Engineering Tb(III)-functionalized HOF Fluorescence Sensing System for Intelligent Visual Detection of Two Biomarkers of Hepatocellular Carcinoma

An optical hemoglobinometer for whole blood

Signal Quality in Continuous Transcutaneous Bilirubinometry

Turn-Off Fluorometric Determination of Bilirubin Using Facile Synthesized Nitrogen-Doped Carbon Dots as a Fluorescent Probe

Folic acid capped bimetallic nanoparticle based fluorescence sensor for the nanomolar determination of bilirubin

A New Bilirubin Concentration Detection Method by Light Reflection

Development of a Portable and Sensitive Blood Serum Test System Using LED-based Absorption Photometry and Pump-Free Microfluidic Technology

Noninvasive direct bilirubin detection by spectral analysis of color images using a Mini-LED light source